Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) stock jumped 10.71% on Friday to $1.86 against a previous-day closing price of $1.68. With 24.92 million shares changed hands, the volume of the stock remained heavier than its average volume of 9.55 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.1400 whereas the lowest price it dropped to was $1.8500. The 52-week range on TNXP shows that it touched its highest point at $26.08 and its lowest point at $1.19 during that stretch. It currently has a 1-year price target of $40.67. Beta for the stock currently stands at 1.61.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of TNXP was up-trending over the past week, with a rise of 7.51%, but this was up by 17.72% over a month. Three-month performance dropped to -60.16% while six-month performance fell -73.97%. The stock lost -91.88% in the past year, while it has lost -83.75% so far this year. A look at the trailing 12-month EPS for TNXP yields -7.60 with Next year EPS estimates of -6.37. For the next quarter, that number is -1.45. This implies an EPS growth rate of 53.60% for this year and -5.00% for next year.
Float and Shares Shorts:
On Apr 28, 2022, short shares totaled 45.07 million, which was 8.44% higher than short shares on Mar 30, 2022. In addition to Dr. Seth Lederman M.D. as the firm’s Co-Founder, Pres, CEO & Chairman, Mr. Bradley Saenger CPA, CPA serves as its CFO & Treasurer.
Through their ownership of 21.69% of TNXP’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 7.18% of TNXP, in contrast to 11.59% held by mutual funds. Shares owned by individuals account for 0.15%. As the largest shareholder in TNXP with 5.12% of the stake, BlackRock Fund Advisors holds 959,928 shares worth 959,928. A second-largest stockholder of TNXP, Renaissance Technologies LLC, holds 600,014 shares, controlling over 3.20% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in TNXP, holding 560,912 shares or 2.99% stake. With a 2.87% stake in TNXP, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 537,707 shares are owned by the mutual fund manager. The Vanguard Extended Market Index Fu, which owns about 0.98% of TNXP stock, is the second-largest Mutual Fund holder. It holds 183,041 shares valued at 0.29 million. Fidelity Small Cap Index Fund holds 0.64% of the stake in TNXP, owning 119,744 shares worth 0.19 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for TNXP since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With TNXP analysts setting a high price target of $10.00 and a low target of $10.00, the average target price over the next 12 months is $10.00. Based on these targets, TNXP could surge 437.63% to reach the target high and rise by 437.63% to reach the target low. Reaching the average price target will result in a growth of 437.63% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. TNXP will report FY 2022 earnings on 03/13/2023. Analysts have provided yearly estimates in a range of -$6.12 being high and -$6.17 being low. For TNXP, this leads to a yearly average estimate of -$6.14. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Tonix Pharmaceuticals Holding Corp. surprised analysts by -$0.11 when it reported -$1.60 EPS against a consensus estimate of -$1.49. The surprise factor in the prior quarter was -$0.32. Based on analyst estimates, the high estimate for the next quarter is -$1.43 and the low estimate is -$1.46. The average estimate for the next quarter is thus -$1.45.
Summary of Insider Activity:
Insiders traded TNXP stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.